Janney Montgomery Scott LLC Purchases 775 Shares of Genmab A/S (NASDAQ:GMAB)

Janney Montgomery Scott LLC raised its position in Genmab A/S (NASDAQ:GMABGet Rating) by 8.0% in the 3rd quarter, Holdings Channel.com reports. The firm owned 10,416 shares of the company’s stock after buying an additional 775 shares during the period. Janney Montgomery Scott LLC’s holdings in Genmab A/S were worth $335,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of GMAB. Private Capital Group LLC increased its stake in shares of Genmab A/S by 14.1% in the second quarter. Private Capital Group LLC now owns 2,677 shares of the company’s stock valued at $87,000 after buying an additional 331 shares during the period. Private Advisor Group LLC increased its stake in shares of Genmab A/S by 2.0% in the second quarter. Private Advisor Group LLC now owns 20,522 shares of the company’s stock valued at $666,000 after buying an additional 403 shares during the period. Veriti Management LLC increased its stake in shares of Genmab A/S by 8.0% in the second quarter. Veriti Management LLC now owns 10,863 shares of the company’s stock valued at $353,000 after buying an additional 809 shares during the period. Synovus Financial Corp increased its stake in shares of Genmab A/S by 1.1% in the second quarter. Synovus Financial Corp now owns 94,149 shares of the company’s stock valued at $3,060,000 after buying an additional 986 shares during the period. Finally, Sawtooth Solutions LLC increased its stake in shares of Genmab A/S by 5.9% in the second quarter. Sawtooth Solutions LLC now owns 18,015 shares of the company’s stock valued at $585,000 after buying an additional 1,000 shares during the period. 6.73% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on GMAB shares. Deutsche Bank Aktiengesellschaft cut Genmab A/S from a “buy” rating to a “hold” rating in a research note on Friday, November 11th. William Blair began coverage on Genmab A/S in a research note on Monday, November 14th. They set a “market perform” rating for the company. Citigroup cut Genmab A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 20th. DNB Markets cut Genmab A/S from a “buy” rating to a “hold” rating in a research note on Monday, October 17th. Finally, AlphaValue raised Genmab A/S to a “reduce” rating in a research note on Thursday, November 17th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $632.12.

Genmab A/S Price Performance

Shares of GMAB opened at $39.01 on Wednesday. The firm has a market cap of $25.73 billion, a PE ratio of 31.98, a PEG ratio of 1.14 and a beta of 1.02. The stock’s fifty day moving average price is $43.22 and its two-hundred day moving average price is $38.69. Genmab A/S has a 1 year low of $26.19 and a 1 year high of $47.50.

Genmab A/S (NASDAQ:GMABGet Rating) last issued its earnings results on Wednesday, November 9th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.30. The firm had revenue of $553.71 million for the quarter, compared to analyst estimates of $486.10 million. Genmab A/S had a return on equity of 22.78% and a net margin of 46.32%. Sell-side analysts anticipate that Genmab A/S will post 1.39 earnings per share for the current fiscal year.

About Genmab A/S

(Get Rating)

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.

Featured Stories

Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMABGet Rating).

Institutional Ownership by Quarter for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.